エピソード

  • GLS Vitals Episode 12 - Moving Quickly with a Long-Term Strategy: Building a Scrappy Rare Disease Company
    2026/08/13
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCES

    In this episode Georgia Life Sciences President & CEO, Maria Thacker Goethe, sits down with Dave Penake, CEO of Saol Therapeutics and Chair of Georgia Life Sciences, for a conversation about leadership, biotech growth, rare disease innovation, and the future of Georgia’s life sciences ecosystem.Drawing on a career that has taken him from semiconductor manufacturing to biotech hubs in Boston and the San Francisco Bay Area—and ultimately to Atlanta—Dave shares the experiences that shaped his approach to leadership and his belief in taking a long-term view when building life sciences companies.

    The conversation explores Saol Therapeutics’ evolution and pipeline, including the company’s work in rare disease and pain, as well as the difficult strategic decisions involved in financing, portfolio development, partnerships, and determining when another organization may be better positioned to advance an innovation. Dave also discusses the importance of patient communities and how their experiences continue to motivate the Saol team.

    Maria and Dave then turn to Georgia’s growing life sciences ecosystem. Having worked in Boston and the Bay Area before spending nearly a decade in Atlanta, Dave shares why he sees Georgia’s talent, universities, infrastructure, workforce retention, and quality of life as significant competitive advantages. He also discusses opportunities to strengthen the connection between university innovation, entrepreneurship, capital, company formation, and commercial-scale growth.

    As Chair of Georgia Life Sciences, Dave also shares his priorities for the organization, including executing Georgia’s life sciences roadmap, aligning leaders across the ecosystem, measuring progress, and building greater support for the industry.

    The episode closes with a look at what gives Dave optimism about the future—from accelerating technological advances that could unlock new treatments and cures to growing global competition that may push the U.S. life sciences industry to innovate even faster. In this episode:
    • Building and leading a life sciences company for the long term
    • Advancing therapies for rare diseases and unmet patient needs
    • Making difficult decisions around capital, partnerships, and growth
    • Knowing when to build, partner, license, or hand off an innovation
    • Why Georgia can compete as a leading life sciences hub
    • Connecting university research with entrepreneurs and capital
    • Executing Georgia’s life sciences industry roadmap
    • The future of biotechnology, innovation, and U.S. competitiveness
    About Georgia Life Sciences

    As the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences’ mission is to advance the growth of Georgia’s life sciences industry through partnerships and initiatives that accelerate innovation, investment, and job creation. To accomplish this mission, Georgia Life Sciences conducts economic development activities; advocates on behalf of its members on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for idea exchange and cooperation.

    For more information on the impactful work, to join as a member, or provide support to the mission, please visit Georgia Life Sciences at https://www.galifesciences.org/

    About Cloudcast Media

    As the national leader in local podcasting to create a "listen where you live" mindset, Cloudcast Atlanta, a division of Cloudcast Media, proudly produces "VITALS: The Pulse of Georgia Life Sciences" through its CauseCast platform to help amplify, augment, and accelerate the mission and reach of community social impact organizations. For more information on Cloudcast Media, please visit their website at CloudCast Media.

    This episode was produced by Senior Associate Producer Brandon Joe. The episode was recorded, engineered, mixed and mastered by Sky Guides Atlanta, the podcast program and studio affiliated with the Russell Innovation Center for Entrepreneurs (RICE) in Atlanta, Georgia.
    続きを読む 一部表示
    38 分
  • GLS Vitals Episode 11 - Building Tomorrow: Biotech, Innovation, Talent & Growth
    2026/07/28
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCES

    In this episode of Vitals: Georgia's Life Sciences Podcast, Georgia Life Sciences President & CEO Maria Thacker Goethe sits down with Helen Tarlatin, Director of Employee & Community Engagement at UCB, to discuss one of the most significant life sciences investments in Georgia's history. Fresh off UCB's announcement of its $2 billion biologics manufacturing facility in Gwinnett County, Helen shares why Georgia emerged as the ideal location, what this investment means for patients, and how workforce development, education, and community partnerships are shaping the next generation of biotechnology manufacturing. The conversation explores how industry, education, government, and nonprofits must work together to build the skilled workforce needed to support America's growing life sciences sector. Topics include:
    • Why UCB selected Georgia for its first U.S. branded biologics - manufacturing facility
    • The strategic importance of domestic pharmaceutical manufacturing
    • Building a sustainable life sciences workforce and talent pipeline
    • The role of Georgia's universities, technical colleges, and workforce partners
    • STEM education and inspiring future biotechnology careers
    • Leadership lessons on collaboration, transparency, and community engagement
    • Georgia's emergence as a national hub for biotechnology and advanced manufacturing
    • How public-private partnerships strengthen economic development and innovation
    Whether you're a biotechnology executive, entrepreneur, educator, student, policymaker, or simply interested in the future of healthcare innovation, this episode offers valuable insights into the investments and partnerships transforming Georgia into one of America's leading life sciences ecosystems.

    About Georgia Life Sciences

    As the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences’ mission is to advance the growth of Georgia’s life sciences industry through partnerships and initiatives that accelerate innovation, investment, and job creation. To accomplish this mission, Georgia Life Sciences conducts economic development activities; advocates on behalf of its members on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for idea exchange and cooperation.

    For more information on the impactful work, to join as a member, or provide support to the mission, please visit Georgia Life Sciences at https://www.galifesciences.org/

    About Cloudcast Media

    As the national leader in local podcasting to create a "listen where you live" mindset, Cloudcast Atlanta, a division of Cloudcast Media, proudly produces "VITALS: The Pulse of Georgia Life Sciences" through its CauseCast platform to help amplify, augment, and accelerate the mission and reach of community social impact organizations. For more information on Cloudcast Media, please visit their website at CloudCast Media.

    This episode was produced by Senior Associate Producer Brandon Joe. The episode was recorded, engineered, mixed and mastered by Sky Guides Atlanta, the podcast program and studio affiliated with the Russell Innovation Center for Entrepreneurs (RICE) in Atlanta, Georgia.
    続きを読む 一部表示
    38 分
  • GLS Vitals Episode 10 - Building the Future - Biotech Leadership & Global Impact
    2026/06/10
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESDavid Dodd, CEO of Geovax, discussed the evolution of Georgia's life sciences ecosystem, emphasizing the persistence and collaboration of various stakeholders over decades. Geovax's focus is on developing the Geo MVA vaccine for monkeypox and smallpox, leveraging a platform with no contraindications. The company aims to establish advanced MVA manufacturing in Georgia, initially employing 25-50 people, expanding to 100+. Dodd highlighted the critical need for sustained investment in vaccine innovation and manufacturing to ensure global health security. He also stressed the importance of education and workforce development in fostering a robust life sciences ecosystem.David Dodd's Journey and Georgia's Life Sciences EcosystemMaria Thacker introduces David Dodd, CEO of Geovax, and highlights his long-standing involvement in Georgia's life sciences community.David Dodd reflects on the persistence and commitment of people in building Georgia's life sciences ecosystem over decades.David emphasizes the importance of resilience, capital scarcity, and long timelines in the biotech industry.Maria and David discuss the evolution of Georgia's life sciences hub, noting increased connectivity and awareness of Georgia's opportunities.David Dodd's Career Path and Personal JourneyDavid Dodd shares his career journey, starting in 1977 with Abbott Laboratories and progressing through various roles in big pharma, including Bristol Myers Squibb and Wyeth.David highlights his experience as CEO of Solvay Pharmaceuticals and his role in transforming the company's value from $100 million to $2.5 billion.David discusses his transition to NASDAQ companies and his involvement with Geovax, eventually becoming its CEO in 2018.David mentions his multiple attempts to retire and his current satisfaction with his work and the support of his wife.Geovax's Evolution and EnduranceDavid explains Geovax's evolution from a single-product HIV vaccine focus to a broader infectious disease vaccine platform.He highlights the relevance of Geovax's vaccine platform, which was used to eradicate smallpox and has been repurposed for other infectious diseases.David discusses the challenges of adapting to changing markets, funding environments, and public health priorities.He emphasizes the importance of disciplined prioritization, scientific credibility, and the ability to adapt in a challenging environment.Manufacturing Challenges and PreparednessDavid elaborates on the infrastructure-intensive nature of vaccine development and the unique challenges of manufacturing vaccines.He discusses the critical role of quality systems, regulatory alignment, and supply chain depth in vaccine manufacturing.David highlights the importance of sustained investment in preparedness between crises to avoid rebuilding capacity during emergencies.He provides examples of the impact of the monkeypox outbreak and the need for a global supply of vaccines.Geovax's Focus on Geo MVA and Clinical TrialsDavid outlines Geovax's current focus on Geo MVA, a vaccine candidate for monkeypox and smallpox preparedness.He explains the expedited regulatory path granted by the European Medicines Agency (EMA) for Geo MVA.David details the manufacturing process and the challenges of producing MVA vaccines quickly.He discusses the company's plans to establish advanced MVA manufacturing in Georgia and the support from state and federal legislators.Georgia's Role in Vaccine Innovation and BiosecurityDavid emphasizes the importance of Georgia's role in vaccine innovation and biosecurity.He highlights the state's potential to become a hub for vaccine innovation and biosecurity, leveraging its academic institutions and growing venture activity.David discusses the need for sustained investment in infrastructure and talent to support the life sciences ecosystem.He mentions the importance of collaboration and integration within the ecosystem to achieve long-term success.Leadership and Decision-Making in BiotechDavid shares his leadership philosophy, emphasizing the importance of execution, science, and talent development.He discusses the challenges of prioritizing multiple global health threats and the need for exquisite focus on critical programs.David highlights the importance of mentoring and staff development in building a strong team.He reflects on the evolution of Georgia's life sciences ecosystem and the role of policy makers and legislators in supporting the industry.Georgia's Life Sciences Ecosystem and Future ProspectsDavid expresses pride in the progress of Georgia's life sciences ecosystem and its potential to become a legitimate life sciences hub.He discusses the importance of long-term planning and investment in education and workforce development.David highlights the need for continued collaboration and support from the state and federal government to achieve the ecosystem's goals.He emphasizes the importance of maintaining ...
    続きを読む 一部表示
    1 時間 14 分
  • GLS Vitals Episode 9 - Building What Matters: Leadership, Manufacturing & Growth in Life Sciences
    2026/06/10
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESScott Rizzo, Vice Chair of Georgia Life Sciences, discussed his career journey from the automotive industry to pharmaceutical manufacturing, highlighting his roles at Hoffman Roche, Barrier Therapeutics, and Recrow Pharma. He emphasized the importance of local government support and the recent $20 million expansion of Bend, a CDMO in Gainesville, Georgia, which will create additional jobs. Rizzo stressed the need for collaboration among life sciences companies, effective supply chain management, and the integration of AI to enhance drug development and manufacturing. He also underscored the importance of workforce development and communication with educational institutions to foster a robust life sciences ecosystem in Georgia.Scott Rizzo's Career Journey and Role in Georgia Life SciencesMaria Thacker introduces Scott Rizzo, highlighting his leadership in the manufacturing space for life sciences.Scott shares his career journey, starting in the automotive industry in the late 80s and early 90s, then moving to consulting and eventually to the pharmaceutical industry.Scott details his roles at Hoffman Roche, Barrier Therapeutics, J Nipper, and Recrow Pharma, leading to his current position as a board member and COO.Scott mentions the significant impact of a strong cup of coffee in his decision to move to Georgia in 2015.Educational Background and Industry InsightsScott discusses his educational background, including a degree in political science and an MBA with a focus on supply chain and finance from Penn State.Maria emphasizes the diverse backgrounds in the life sciences industry and the importance of various educational paths.Scott provides more details about the history of Recrow Pharma and its evolution through acquisitions and rebranding.Scott highlights the welcoming and supportive environment he experienced in Georgia, particularly in Gainesville, which influenced his decision to contribute to the life sciences industry in the state.Bend's Expansion and Investment in GeorgiaMaria and Scott discuss Bend's recent groundbreaking for a significant expansion in Georgia, highlighting the $20 million investment and additional jobs.Scott explains the strategic fit of bringing commercial spray drying technology to Gainesville, leveraging the site's existing expertise and infrastructure.The expansion is seen as a positive step for the company and the state, with strong support from local government and community.Scott emphasizes the importance of the state's infrastructure, including the Port of Savannah and the Blue Ridge Connector, in supporting the expansion.Bend's Role as a CDMO and Industry TrendsScott explains Bend's role as a CDMO (Contract Development and Manufacturing Organization) and its capabilities in commercial manufacturing and development projects.Bend has a balance between commercial and development projects, working with small clients and providing a range of services.Scott discusses the importance of capacity, technology, and understanding customer pipelines in the CDMO space.Scott highlights the increasing demand for onshoring and the importance of speed and communication in the industry.Challenges and Opportunities in Scaling ManufacturingScott elaborates on the concept of "ready to scale" and the complexities involved, including supply chain management and communication with clients.He emphasizes the importance of having systems in place to manage risks and ensure consistency in manufacturing.Scott discusses the evolving role of AI in the pharmaceutical industry, from procurement to creating optimal formulas and personalized medicine.The focus on AI should always be on improving patient outcomes and making drugs available faster.Building a Workforce for Innovation and ManufacturingScott suggests that better communication with universities and high schools is crucial for building a workforce that supports innovation and large-scale manufacturing.He emphasizes the importance of creating awareness and understanding of the pharmaceutical manufacturing industry among young students.Scott calls for more open communication among life science companies in Georgia to share knowledge and best practices.He highlights the need for a collaborative approach to training and developing talent in the state.Georgia's Ecosystem and Future GrowthScott praises Georgia's ecosystem, including its infrastructure, ports, and supportive government, as key factors in attracting and retaining life science companies.He suggests that more proactive outreach to top pharma companies could help Georgia position itself as a prime location for new investments.Scott believes that once companies are in Georgia, they are likely to stay due to the state's many benefits.He emphasizes the importance of showcasing Georgia's strengths and opportunities to attract new investments and talent.Scott's Personal Interests and Commitment to GeorgiaScott shares his personal interests...
    続きを読む 一部表示
    43 分
  • GLS Vitals Episode 8 - Smart Capital Wins: Funding Strategy & Leadership In Life Sciences
    2026/06/10
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESCourtney Law, Vice President of Innovation Economy at J.P. Morgan, discussed her career journey from PhD training to her current role, emphasizing the importance of ecosystem building and leveraging resources. She highlighted the positive investment environment in the Southeast, noting a significant uptick in biopharma venture funding and the highest med tech venture activity globally in Q4. Challenges include regulatory changes and funding gaps for early-stage companies. Law stressed the importance of communication, patience, and advocacy for early-stage funding. She also underscored Georgia's strengths, including a robust university system, talent pool, and the need for more affordable lab space to support growth.Role at J.P. Morgan and Scientific BackgroundCourtney explains how her scientific background helps her evaluate life science companies and their leadership teams.She highlights the importance of establishing common ground with early-stage founders and company leads through her scientific understanding.Courtney discusses the role of her current position at J.P. Morgan in leveraging internal resources to connect innovators.Maria Thacker and Courtney discuss the importance of ecosystem building and the role of trade associations in supporting innovation.Current Investment Environment for Life Science CompaniesCourtney provides an overview of the current investment environment for life science companies, focusing on biopharma and med tech.She notes a significant uptick in venture funding in biopharma and a high volume of venture deals and money in the med tech space in Q4.Courtney highlights the role of licensing and M&A activity in driving innovation and funding.Maria Thacker and Courtney discuss the unique challenges faced by innovators in the current regulatory environment.Capital Strategies and Challenges for Early-Stage CompaniesCourtney explains the divide in venture investment between pre-series A/series A and series B+ companies, with investors being more risk-averse.She mentions early-stage companies looking to family offices and philanthropic dollars to bridge funding gaps.Courtney discusses the importance of over-communication and patience for early-stage companies in navigating the current environment.Maria Thacker and Courtney highlight the challenges of connecting with family offices and other resources in regions with fewer investors.Georgia's Life Sciences Landscape and Regional StrengthsCourtney assesses Georgia's life sciences landscape, noting the growth and momentum in the region.She highlights the strengths of Georgia's university system, innovation engine, and talent pool.Courtney discusses the overlooked aspect of people's love for living in Georgia and their desire to contribute to the ecosystem.Maria Thacker and Courtney discuss the importance of access to affordable quality lab space and the need for new lab space in Georgia.Building and Supporting the Innovation EcosystemCourtney emphasizes the importance of building upon the existing community and access to capital in Georgia.She discusses the role of new funds and lab space in supporting the growth of early-stage companies.Maria Thacker and Courtney highlight the importance of government support and engagement with trade associations for early-stage funding.Courtney encourages companies to advocate for themselves and explore different avenues for funding and support.Leadership and Resilience in Dynamic MarketsCourtney identifies over-communication and nimbleness as key attributes of resilient leadership teams.She emphasizes the importance of staying steadfast to the mission and making decisions to react to changing environments.Maria Thacker and Courtney discuss the role of trade associations in advocating for the industry and engaging with government leaders.Courtney advises companies to focus on their next value inflection point when pitching to investors.Final Thoughts and Advice for CEOsCourtney advises CEOs preparing for a major capital raise to focus on communication and patience.She emphasizes the importance of being focused and clear in fundraising pitches.Maria Thacker and Courtney discuss the importance of engaging with trade associations and advocating for early-stage funding.Courtney shares a personal anecdote about her competitive nature and love for trying new recipes at home.About Georgia Life SciencesAs the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences’ mission is to advance the growth of Georgia’s life sciences industry through partnerships and initiatives that accelerate innovation, investment, and job creation. To accomplish this mission, Georgia Life Sciences conducts economic development activities; advocates on behalf of its members on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for idea exchange ...
    続きを読む 一部表示
    27 分
  • S2 Ep 7 | Beyond the Diagnosis: Dorothy Leone-Glasser Discusses Empowering Patients and Changing Healthcare Policy in Georgia
    2026/03/09
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESAt the core of every illness is an individual. Obvious, yes, but often the individual's voice is not heard, not empowered, not embraced. In this very robust and thought provoking episode of VITALS, Maria Thacker Goethe, the CEO of Georgia Life Sciences, interviews Dorothy Leone- Glasser, a registered nurse specialist in rheumatology and immunology, who shared her journey with systemic lupus, emphasizing the importance of personal responsibility and lifestyle changes. She highlighted the need for patient engagement and advocacy, particularly in clinical trials and healthcare policy. Leone-Glasser discussed her organization, Advocates for Responsible Care (ARxC), which focuses on issues like pharmacy benefit managers (PBMs), cancer early detection, and the 340B program. She stressed the importance of collaboration between patients, industry, and policymakers to improve healthcare outcomes and called for increased patient and caregiver involvement in advocacy efforts.Dorothy Leone-Glasser's Patient Journey and Early CareerDorothy shares her patient story, detailing her critical illness at 19, including symptoms of arthritis, stroke, heart attack, and coma.It took five years to diagnose her with systemic lupus, which included right-sided kidney failure.Despite her illness, Dorothy emphasizes the importance of personal responsibility in managing her health and lifestyle changes.Challenges and Advocacy in HealthcareDorothy discusses the challenges she faced in her medical training and the lack of disability rights during her time.She transitioned into psychoneuroimmunology and wellness counseling to help other patients, focusing on personal empowerment.Dorothy became an advocate, insisting on being part of her treatment plan and actively engaging in her wellness.She highlights the importance of community and support systems for patients, sharing her experiences with the Arthritis Foundation and other rare disease communities.Impact of Healthcare System on PatientsDorothy reflects on the changes in the healthcare system since her early days, noting the increased politics, profiteering, and corruption.She emphasizes the need for a holistic view of the patient, beyond just the medical condition.Dorothy's philosophy is that illness lives in the mind and plays out in the body, but it finds peace in the spirit.She shares her work in thanatology and the importance of living a meaningful life and dying in peace.Community and Patient AdvocacyDorothy stresses the importance of finding a community and engaging with other patients to strengthen each other.She discusses the role of patient advocacy in healthcare, emphasizing the need for patients to have a voice and be part of the treatment plan.Maria and Dorothy discuss the challenges of isolation for patients and the importance of community support.Dorothy highlights the need for collaboration between patients, industry, and policymakers to improve healthcare outcomes.Advocates for Responsible Care (ARxC) and Its MissionDorothy explains the formation of ARxC and its mission to advocate for responsible care, particularly for patients in crisis situations.She shares an example of ARxC's work with Grady Hospital's outpatient dialysis clinic and the challenges faced by patients.ARxC's focus is on empowering patients and advocating for their rights, often representing patients who fall through the cracks of the healthcare system.Dorothy emphasizes the importance of empathy and accountability in healthcare, particularly for underserved communities.Legislative Priorities and ChallengesDorothy outlines ARxC's legislative priorities for the upcoming session, including pharmacy benefit managers (PBMs), cancer early detection, and the 340B program.She discusses the challenges of getting legislation passed due to the focus on campaigning during election years.Dorothy emphasizes the importance of transparency and accountability in healthcare, particularly in programs like the 340B Drug Pricing Program.She highlights the need for federal legislation to be consistent across states and the importance of state-level advocacy.Collaboration and Engagement with IndustryDorothy and Maria discuss the importance of collaboration between patients, industry, and policymakers to improve healthcare outcomes.They emphasize the need for industry to engage with patient advocates and understand the patient perspective.Dorothy shares her experiences with ARxC's coalition with organizations such as Reach Georgia, and the importance of having a unified voice.They discuss the challenges of getting industry to support patient advocacy and the need for more investment in patient care.Patient Advocacy and Legislative EngagementDorothy and Maria discuss the importance of patient advocacy and legislative engagement for improving healthcare.They highlight the need for patients to be more engaged in their care and to advocate for their rights.Dorothy ...
    続きを読む 一部表示
    56 分
  • S2 Ep 6 | Good Science Will Find Funding: Venture Lending, Exits, And Building Talent In Life Sciences
    2026/02/20
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker Goethe, the CEO of Georgia Life Sciences, interviews Scott McCarty, Managing Director of Sales, Origination, Healthcare and Life Sciences at Silicon Valley Bank, who discusses venture debt strategy, cautious optimism in today’s market cycle, robust biotech exits, and how executives can scale healthcare innovation, medtech, and health tech companies across Georgia and the broader Southeast ecosystem.Scott McCarty's Career JourneyMaria Thacker Goethe asks Scott McCarty about his career journey, starting with his background in finance at UGA and his initial aversion to commercial banking.Scott shares his experience of joining Silicon Valley Bank (SVB) through a friend, finding it more entrepreneurial and less stodgy than traditional banks.Scott describes the growth of SVB, from a regional bank to a significant player with $230 billion in total assets before merging with First Citizens.Scott emphasizes SVB's continued focus on venture debt and healthcare innovation, despite the bank's expansion and changes.SVB's Role in Venture Lending and Healthcare InnovationMaria inquires about SVB's current structure and its role in venture lending and healthcare innovation.Scott explains that SVB is still a major player in venture lending, particularly in the healthcare innovation space.Scott discusses the evolution of SVB's healthcare and life sciences business, which has become a significant growth engine for the bank.Scott notes the increased competition in the market, with many former SVB colleagues starting new ventures, but maintains that SVB remains a friendly competitor.Scott McCarty's Current Role and ResponsibilitiesMaria asks about Scott McCarty's current role and responsibilities.Scott describes his initial role in starting a team in the mid-Atlantic and southeast, covering from Philadelphia to Miami.Scott explains the evolution of his role into a national sales role, working with all eight of SVB's teams and focusing on growth-stage companies.Scott highlights the shift in Series A funding, with larger Series A rounds now common in the biotech space.Georgia's Life Sciences Ecosystem and Personal BackgroundMaria asks about Scott's personal background and his time in Georgia.Scott shares his history of moving frequently due to his father's job at IBM, eventually settling in Georgia.Scott mentions his high school experience at Chattahoochee High School, part of the first graduating class.Maria and Scott discuss the evolution of company building over the past 20 years, noting the shift towards more virtual companies and the challenges of retaining local talent.Market Outlook for 2026 and JPM Healthcare WeekMaria asks about the market outlook for 2026 and the impact of the upcoming JPM Healthcare Week.Scott expresses cautious optimism, noting the low fundraising environment of the past few years and the need for high-end announcements at JPM.Scott discusses the importance of maintaining a robust exit environment to keep the market healthy.Scott highlights the role of AI in healthcare innovation, particularly in drug discovery and data analysis, and its potential to drive investment.Challenges for Early-Stage Companies and Strategic AdviceMaria asks for advice for early-stage companies struggling to raise capital.Scott emphasizes the importance of surrounding oneself with good advisors and having a strong story to tell.Scott advises early-stage entrepreneurs to be receptive to feedback and to leverage conferences and networking opportunities.Scott discusses the role of family offices and private high net worth offices in funding early-stage companies and the challenges of accessing these funds.Investment and Exit Themes for the Next 12-24 MonthsMaria inquires about major investment and exit themes for the next 12-24 months.Scott notes the continued importance of venture fundraising, despite the current low levels, and the role of established funds in deploying capital.Scott highlights the importance of maintaining a robust exit environment, with a focus on mid-range exits in addition to the large ones.Scott discusses the role of AI in healthcare innovation and its potential to drive investment and growth.Venture Debt and Capital StrategyMaria asks about the role of venture debt and capital strategy in the industry.Scott explains the importance of using venture debt alongside equity to extend cash runway and achieve higher valuations.Scott discusses the competitive landscape for venture debt, with both banks and debt funds vying for market share.Scott emphasizes the importance of selecting the right capital partner, one that offers sector expertise and a strong network.Georgia's Life Sciences Ecosystem and Future GrowthMaira asks about the current state of Georgia's life sciences ecosystem and its future growth potential.Scott notes the maturation of the ecosystem, with a focus on ...
    続きを読む 一部表示
    40 分
  • S2 Ep5 | Lynn Durham, President & CEO, Georgia Core, A Neutral Party In Cancer Care: Collaboration, Clinical Trials, and Quality of Life
    2026/01/13
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker, the CEO of Georgia Life Sciences, interviews Lynn Durham, President and CEO of Georgia Core, who discusses her journey from government and politics to leading a nonprofit focused on cancer care. Georgia Core, founded in 2003, aims to improve cancer care through research, education, and advocacy. The organization collaborates with healthcare systems across Georgia, emphasizing patient-centered care and clinical trials. Durham highlighted the importance of diversifying funding sources, including federal grants and industry partnerships. She also mentioned the Georgia Cancer Trial Finders program and a statewide colorectal cancer awareness campaign. Durham's personal experiences with cancer and her commitment to improving cancer care drive her work.Lynn Durham's Journey and Role at Georgia CoreMaria introduces Lynn Durham, President and CEO of Georgia Core, and highlights the importance of her work in the oncology space.Lynn shares her career journey, starting with her work at Georgia Tech in government and politics, and her transition to becoming the president's chief of staff.Lynn discusses her personal connection to cancer, having survived thyroid, breast, and chronic myeloid leukemia, and her involvement with Georgia Core's survivorship advisory board.Lynn explains how she was asked to lead Georgia Core after the previous president retired, despite her initial plans to pursue higher education.Georgia Core's Mission and StructureMaria asks about the meaning of "core," which stands for the Center for Oncology Research and Education.Lynn explains that Georgia Core was founded in 2003 by Governor Roy Barnes to ensure Georgians had access to cancer care without leaving the state.Georgia Core works with doctors, hospitals, and healthcare systems to improve cancer care through research, education, and advocacy.The organization is not patient-facing but focuses on connecting researchers, providers, and patients to improve cancer care outcomes.Collaboration and Advocacy EffortsLynn emphasizes the importance of collaboration among physicians, administrators, and researchers to improve cancer care in Georgia.Georgia Core has a strong board of 20 members, mostly oncologists, who work together to benefit Georgians.The organization works with various healthcare systems across the state, including Northside, Emory, and Valdosta, to address different cancer care needs in different regions.Lynn highlights the role of advisory boards and regional cancer coalitions in ensuring patient voices are integrated into research and care delivery.Funding and DiversificationLynn discusses the funding sources for Georgia Core, including state funds, federal grants, and industry partnerships.The organization has diversified its funding sources to include federal grants and industry sponsorships, reducing dependence on state funds.Georgia Core also generates funds through license plates and a state income tax line for cancer research.The organization funds seed grants for university researchers and supports nonprofits to provide cancer screenings and other services.Policy and Advocacy ChallengesLynn addresses the challenges posed by uncertain federal and state policies on healthcare access, research funding, and drug pricing.The uncertainty has impacted Georgia Core's ability to plan and secure funding for long-term projects.The organization has had to adapt to changes in funding availability, including the need to hire clinical research nurses and navigators.Lynn emphasizes the importance of advocacy and working with legislators to ensure continued support for cancer care initiatives.Workforce Development and Oncology TalentLynn discusses the challenges of workforce development in the oncology field, including recruitment and retention in rural areas.Georgia Core has established a Cancer Care Access Committee to address workforce issues, including oncology nurses, PAs, and navigators.The organization is working with the Technical College System of Georgia and AHEC to introduce students to oncology careers and develop apprenticeship programs.Lynn highlights the need for legislative support to provide loan forgiveness for healthcare professionals working in rural areas.Innovative Programs and InitiativesLynn introduces the Georgia Cancer Trial Finders program, which helps patients and caregivers find clinical trials for various cancer types.The program has received over 90 referrals and is proving to be a valuable resource for patients and researchers.Georgia Core has launched a statewide colorectal cancer awareness campaign targeting people aged 25 to 54, aiming to increase awareness and early detection.The campaign includes creative elements like "weird looking stools" in bars and coffee shops to raise awareness about colorectal cancer symptoms.Personal Motivation and Future OutlookLynn shares her ...
    続きを読む 一部表示
    34 分